Publicación:
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Vista sencilla de ítem
dc.creatorXu, Xin
dc.creatorSun, Jian
dc.creatorNie, Sheng
dc.creatorLi, Huiyuan
dc.creatorKong, Yaozhong
dc.creatorLiang, Min
dc.creatorHou, Jinlin
dc.creatorHuang, Xianzhong
dc.creatorLi, Dongfeng
dc.creatorMa, Tean
dc.creatorPeng, Jiaqing
dc.creatorGao, Shikui
dc.creatorShao, Yong
dc.creatorZhu, Hong
dc.creatorLau, Johnson Yiu Nam
dc.creatorWang, Guangyu
dc.creatorXie, Chunbao
dc.creatorJiang, Li
dc.creatorHuang, Ailong
dc.creatorYang, Zhenglin
dc.creatorZhang, Kang
dc.creatorHou, Fan Fan
dc.date.accessioned2020-07-17T19:33:15Z
dc.date.available2020-07-17T19:33:15Z
dc.date.created2020-06-05
dc.description.abstractenglishDetection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5–4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5–2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.spa
dc.format.extent9 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41591-020-0949-6spa
dc.identifier.issn1546-170Xspa
dc.identifier.otherhttps://www.nature.com/articles/s41591-020-0949-6#article-infospa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10792
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.keywordSeroprevalence of immunoglobulin M and Gspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleSeroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in Chinaspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa
dspace.entity.typePublication

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41591-020-0949-6.pdf
Tamaño:
1.6 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS